[1] 何广思, 蒋宗惠, 章敢. 替吉奥单药与XELOX方案一线治疗老年晚期胃癌的疗效比较[J]. 蚌埠医学院学报, 2017, 42(2): 185.
[2] 赵灵颖, 张文青, 李存玺, 等. 阿帕替尼抗肿瘤作用机制研究进展[J]. 肿瘤防治研究, 2021, 48(1): 7.
[3] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394. doi: 10.3322/caac.21492
[4] WAGNER AD, SYN NL, MOEHLER M, et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2017, 8: Cd004064.
[5] FERRARA N, GERBER HP, LECOUTER J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6): 669. doi: 10.1038/nm0603-669
[6] ORDITURA M, GALIZIA G, LIETO E, et al. Treatment of esophagogastric junction carcinoma: an unsolved debate[J]. World J Gastroenterol, 2015, 21(15): 4427. doi: 10.3748/wjg.v21.i15.4427
[7] 何捷. 阿帕替尼联合化疗治疗晚期胃癌疗效观察[J]. 中国药物与临床, 2020, 20(11): 1882.
[8] LI J, QIN S, XU J, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13): 1448. doi: 10.1200/JCO.2015.63.5995
[9] 刘朝敏, 王少龙, 姜鹤群, 等. 阿帕替尼对二线化疗失败的晚期胃癌患者预后的影响[J]. 成都医学院学报, 2018, 13(2): 158.
[10] 朱海峰, 李峰. 甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J]. 承德医学院学报, 2019, 36(5): 383.
[11] 王凤霞. 甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性研究[J/CD]. 临床医药文献电子杂志, 2019, 6(62): 74.
[12] 金珊, 蒋莹. 甲磺酸阿帕替尼三线治疗晚期胃癌的疗效和安全性分析[J/CD]. 临床医药文献电子杂志, 2019, 6(50): 55.
[13] ZHANG Y, GOU M, HAN C, et al. Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: a single-center observational study[J]. Anticancer Drugs, 2018, 29(2): 184.